Literature DB >> 12920220

Grading of atypia in nevi: correlation with melanoma risk.

Montserrat Arumi-Uria1, N Scott McNutt, Bridget Finnerty.   

Abstract

Nevi with architectural disorder and cytologic atypia of melanocytes (NAD), aka "dysplastic nevi," have varying degrees of histologic abnormalities, which can be considered on a spectrum of grades of atypia. Somewhat controversial and subjective criteria have been developed for grading of NAD into three categories "mild," "moderate," and "severe." Grading involves architectural and cytological features, which often correlate with each other. Architectural criteria were intraepidermal junctional extension beyond any dermal component, complex distortion of rete ridges, and dermal fibrosis. Cytological criteria were based on nuclear size, dispersion of chromatin, prominence of nucleoli, hyperchromasia and variation in nuclear staining. Few tests have been made of the relationship between specific grades of atypia and patient risk for melanoma. Retrospective review of pathology reports was performed on 20,275 nevi examined between 1989 and 1996. From the total, 6,275 were diagnosed as NAD, which were in 4,481 patients. These patients were divided into those whose worst NAD was mild (2,504), moderate (1,657), or severe (320). Review of accession data revealed that a personal history of melanoma was present in 5.7% of patients with mild, 8.1% with moderate, and 19.7% with severe atypia. The male/female ratios were similar in each group. In the three groups, the mean ages of men were similar and of women were similar, but the mean age of men tended to be 6-11 yrs. older than women in each group. Family histories of melanoma were not considered. The odds ratio as a measure of association between NAD and personal history of melanoma, shows an odds ratio of 4.08 (2.91-5.7) for NAD-severe versus NAD mild, odds ratio 2.81 (2-3.95) for NAD-severe versus NAD-moderate and odds ratio 1.45 (1.13-1.87) for NAD moderate versus NAD-mild. These data show that the probability of having personal history of melanoma, for any given NAD patient, correlates with the NAD grade. Likewise, the risk of melanoma is greater for persons who tend to make nevi with high grade histological atypia.

Entities:  

Mesh:

Year:  2003        PMID: 12920220     DOI: 10.1097/01.MP.0000082394.91761.E5

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  20 in total

1.  Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index.

Authors:  D M Berman; S Wincovitch; S Garfield; M J Romeo
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

2.  The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects.

Authors:  Keith Duffy; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2012-07       Impact factor: 11.527

3.  Identification of BRAF mutations in eruptive melanocytic nevi: new insights into melanomagenesis?

Authors:  Jobin K John; Keiran S M Smalley
Journal:  Expert Rev Anticancer Ther       Date:  2011-05       Impact factor: 4.512

4.  Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin.

Authors:  Bernice Y Yan; Sandra Garcet; Nicholas Gulati; Felix Kiecker; Judilyn Fuentes-Duculan; Patricia Gilleaudeau; Mary Sullivan-Whalen; Avner Shemer; Hiroshi Mitsui; James G Krueger
Journal:  Exp Dermatol       Date:  2018-12-21       Impact factor: 3.960

Review 5.  Melanocytic nevi and melanoma: unraveling a complex relationship.

Authors:  W E Damsky; M Bosenberg
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

Review 6.  Chemoprevention of melanoma.

Authors:  Marie-France Demierre; Glenn Merlino
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

7.  Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.

Authors:  Linda Gao; Karin van den Hurk; Peter T M Moerkerk; Jelle J Goeman; Samuel Beck; Nelleke A Gruis; Joost J van den Oord; Véronique J Winnepenninckx; Manon van Engeland; Remco van Doorn
Journal:  J Invest Dermatol       Date:  2014-07-07       Impact factor: 8.551

Review 8.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

9.  Potential use of OCT-based microangiography in clinical dermatology.

Authors:  Utku Baran; Woo June Choi; Ruikang K Wang
Journal:  Skin Res Technol       Date:  2015-09-03       Impact factor: 2.365

Review 10.  Histologic mimics of malignant melanoma.

Authors:  Caroline Bsirini; Bruce R Smoller
Journal:  Singapore Med J       Date:  2018-05-18       Impact factor: 1.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.